Item 2.02 - Results of Operations and Financial Condition: The filing reports Organon & Co.'s financial results and operational performance as of February 12, 2026 Item 5.07 - Regulation FD Disclosure: The company is making a disclosure under Regulation Fair Disclosure, indicating material information is being disclosed to investors Item 9.01 - Financial Statements and Exhibits: The filing…

Our analysis rates this filing CAUTIOUS. Organon & Co. presents an elevated concern profile driven by multiple interconnected headwinds. The company faces a challenging combination of declining core revenues (down 3% in 2025), stagnant forward guidance (flat 2026), and a leadership transition to…

Concern level: HIGH (6.8/10). Key factors: One high-severity risk identified (Women's Health Revenue Decline and Nexplanon Sales Disruption, severity 7/10) representing material headwind in core product category; Full year 2025 revenue declined 3% YoY with flat 2026 guidance at $6.2B—signals business stagnation with no growth expected in forward year; Interim CEO leadership with stated primary…

Notable risk changes: Nexplanon sales disruption quantified at ~$17M impact in Q4 2025 due to identified U.S. wholesaler sales practice cessation - indicates compliance/distribution channel issues requiring corrective action; Full year 2026 guidance flat at $6.2B revenue and $1.9B Adjusted EBITDA (in-line with 2025) - signals no growth expected and potential stagnation in core business; Interim CEO leadership with…

The model predicts OGN will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.